Mayim Bialik's BreakdownPart Two: 50 Million in Funding, 10,000 New Clinics, and the Mistake That Could Kill the Psychedelic Revolution | Dr. Rick DoblinBig Pharma’s Shortcut
41:47–42:41 · 55s
Doblin slams for-profit psychedelic companies for wanting to sell drugs without the costly therapy that makes treatments durable, comparing it to ketamine’s revolving-door model.